Funding Postauthorization Vaccine-Safety Science

N Engl J Med. 2024 Jul 11;391(2):102-105. doi: 10.1056/NEJMp2402379. Epub 2024 Jul 6.

Authors

Daniel A Salmon¹, Walter A Orenstein¹, Stanley A Plotkin¹, Robert T Chen¹

Affiliation

¹ From the Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore (D.A.S.); Emory University, Atlanta (W.O.); the University of Pennsylvania, Philadelphia (S.A.P.); and the Brighton Collaboration, Task Force for Global Health, Decatur, GA (R.T.C.).

PMID: 38973739
DOI: 10.1056/NEJMp2402379

No abstract available

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19 Vaccines* / economics
Consumer Product Safety
Financing, Government* / legislation & jurisprudence
Humans
Product Surveillance, Postmarketing* / economics
United States
United States Food and Drug Administration / economics

Substances

COVID-19 Vaccines